The endogenous opioid system is involved in various aspects of human behavior, including pain (Maarrawi et al., 2013) , addiction (Williams et al., 2009) , reward (Petrovic et al., 2008) and impulsivity (Love et al., 2009 ) as well as social (Hsu et al., 2013) and emotional behavior (Koepp et al., 2009) . Given the widespread use of opioid medication in diverse conditions, including cough suppression, mild and chronic pain, and substance dependence, a fundamental understanding of this neurotransmitter system is essential.
Positron emission tomography (PET) is a sensitive technique that enables the determination of receptor and neurotransmitter levels in the living human brain. The human endogenous opioid system is composed of three subtypes of opioid receptors (mu, delta and kappa), widely distributed throughout the brain. Mu opioid receptors (MOR) are most dense in the caudate and putamen, nucleus accumbens, thalamus, amygdala and the frontal lobe (Mansour et al., 1988) . [
11 C]carfentanil is a highly selective MOR agonist PET radioligand, which can be used to map opioid receptor availability. Some PET radioligands are also able to detect endogenous neurotransmitter release on the basis of competitive binding between the radioligand and the neurotransmitter, or through changes in affinity or expression of the receptor (Paterson et al., 2010) .
Recently, we ) demonstrated significant reduction in [ 11 C]carfentanil binding in several brain regions following an oral d-amphetamine challenge (0.5 mg/kg) in six healthy volunteers. These results were not replicated by Guterstam et al. (Guterstam et al., 2013) using an intravenous 0.3 mg/kg dose of d-amphetamine in 10 healthy volunteers.
This study aimed to replicate our previous study in an independent cohort of nine male healthy volunteers, using an identical study design.
Method
Participants were recruited by advertisements in daily newspapers or from our database. A telephone eligibility interview was followed by a screening visit to comprehensively assess participants' current and previous medical and mental health as well as history of alcohol,
tobacco, and other substance use. Individuals with current or prior psychiatric disorders (ICD-10 or DSM-IV Axis I diagnostic criteria assessed using the modified international neuropsychiatric interview-MINI) were excluded. No participant scored above the threshold for mild-depression (range 0-7, mean 1± 2.3) on the Beck Depression Inventory (BDI).
Current or past history of dependence on substances of abuse, except nicotine, was an exclusion criterion, although previous recreational drug use was allowed. Participants were excluded if they drank more than 21 UK units of alcohol (166 g) per week two weeks before and during study participation. Other drug use (except nicotine) was not allowed two weeks prior and during the inclusion into the study. On both screening and study days, urine drug screen testing for cocaine, amphetamine, methamphetamine, morphine, methadone, benzodiazepines and THC were performed and participants were tested for alcohol using a breathalyzer. Smoking was not allowed at least 1 hour before each scan. All participants had laboratory (haematology, clinical chemistry) and ECG results within normal range. None of the participants were taking regular medication; they had never used antipsychotics or antidepressants. In total, nine male healthy volunteers, including two smokers, mean age 33.1± 6.5 years were included into this study.
On the screening day, participants underwent structural and functional magnetic resonance imaging (MRI); functional MRI results will be reported elsewhere.
Written informed consent was obtained from all participants. The study was approved by the
West London Research Ethics Committee and the Administration of Radioactive Substances
Advisory Committee, UK.
Procedure
The PET imaging procedures were identical to our previous study .
Briefly, participants underwent two between pre-and post-scans in these cases was 14 days (maximum interval 36 days). The oral dose of 0.5 mg/kg d-amphetamine was administered 3 hours before the postamphetamine PET scan, after a light meal. The choice of the time for the post-amphetamine scan was based upon the peak of amphetamine plasma levels reached after 3 hours (Shotbolt et al., 2012) . Blood samples to assess plasma levels were obtained throughout the study day (pre-dosing and 1; 2; 3 and 4.5 hours post-dosing).
Subjective responses to the amphetamine challenge were rated using the simplified version of the amphetamine interview rating scale (SAIRS) (Van Kammen and Murphy, 1975) , consisting of self-ratings for euphoria, restlessness, alertness and anxiety on an analogue scale ranging from 1 (least ever felt) to 10 (most ever felt). The rating scale was administered after the pre-amphetamine PET scan, 15 min pre dosing; 5 min; 1; 2; 3 hours post dosing (before the post-amphetamine PET scan) and 4.5 hours post dosing (after postamphetamine PET scan). Participants also completed the Spielberger state anxiety inventory (SSAI) before and after each PET scan as well as on the screening day. The BDI was used to rule out significant depressive symptoms and was performed on screening and study days.
PET and MR imaging
We followed our PET previous protocol with a minor change in acquisition periods . The dynamic emission data were collected continuously for 90 minutes (26 frames, 8*15 s, 3*60 s, 5*120 s, 5*300 s, 5*600 s, to a total of 5400 s), following an 
. Individual PET frames were corrected for radioactive decay and for head motion using rigid-body co-registration with the 16 th frame as the reference image. The T1-weighted MR image was co-registered to the summed PET image, after brain extraction using the Brain Extraction Tool (Smith, 2002) . The T1 image was segmented into grey, white matter and cerebrospinal fluid. Non-linear deformation parameters were derived for the mapping of the T1 image into stereotaxic space and this enabled the mapping of a stereotaxic atlas (Tziortzi et al., 2011) into the individual's space.
The individualized regions of interest were then applied to the dynamic PET data to derive regional time-activity data for nine regions of interest (ROI). The ROIs examined were:
caudate, putamen, thalamus, cerebellum, frontal lobe, nucleus accumbens, anterior cingulate, amygdala and insula cortices. These regions were chosen a priori based on high relative density of MOR, including those which showed statistical significance in reduction of BP ND in grey-matter masked ROIs was estimated using the simplified reference tissue model (Lammertsma and Hume, 1996) , specifying the occipital lobe as a reference tissue due to the very low regional MOR expression in this region (Hiller and Fan, 1996; Rabiner et al., 2011 Changes in subjective amphetamine ratings, including euphoria and anxiety, were only mildly pronounced. The mean change (∆) in euphoria scores from baseline to 4.5 hours post dosing was +1.11, maximum change was +3. SSAI ratings showed a mean∆ of -6.67, max∆ of -24. An exploratory analysis of the relationship between changes in subjective ratings and regional %∆BP ND did not show any significant correlations (p>0.05).
Pharmacokinetic amphetamine blood sampling Data from samples for amphetamine plasma concentrations was available for seven participants. At 3 hours post-dosing (just before post-amphetamine PET scan), the calculated plasma amphetamine concentration was 89.7± 19.7 ng/ml (mean± SD) (range from 0 ng/ml at baseline to 80.3± 8.1 ng/ml at 4.5 hours post dosing). The relationship between amphetamine plasma concentrations and regional %∆BP ND did not show any significant correlations (p>0.05).
Discussion
We have replicated our previous findings of a reduction in amphetamine plasma levels though with IV administration it is likely that they also were at peak amphetamine levels close to the start of PET scan.
However capturing the peak of amphetamine levels is not the critical measure, rather it is the increase in endogenous opioids to compete with [ 11 C]carfentanil binding. Comparing the outcome of IV with oral amphetamine administration, it appears that time is required to allow endogenous opioids to increase and accumulate such that IV administration followed closely by injection of [ 11 C]carfentanil is too fast. It is certainly true that if the endogenous opioid system plays an important role in acute rewarding effects, the primary drug dosing effect has to be present within minutes; however, the secondary effect of endogenous opioid release in the brain might not be detectable in such an early stage. These studies suggest that time is needed for endogenous opioids to accumulate to be detectable with [ 11 C]carfentanil PET.
In our current study, there were no significant differences in injected [ 11 C]carfentanil mass or injected radioactivity between pre and post-amphetamine scans. This addresses a concern previously raised by Gusterstam et al. and rejects any differences between the previous studies being down to tracer mass or activity.
Another major difference between the two protocols is the participants' subjective response to the amphetamine challenge. The participants in Guterstam et al. study consistent with fast, IV administration reported strong subjective effects, which were not seen in either of our cohorts receiving oral amphetamine. Nevertheless, we were able to detect changes in [ 11 C]carfentanil BP ND without participants experiencing a potentially adverse 'high', as evidenced by the lack of significant changes in the euphoria scores.
In summary, we have replicated our previous findings that endogenous opioid release following an amphetamine challenge can be detected in multiple regions in the living human Frontal lobe + 
